2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes.
2019
Аутори:
Schwarze, BenediktJelača, Sanja
Welcke, Linda
Maksimović-Ivanić, Danijela
Mijatović, Sanja
Hey-Hawkins, Evamarie
Тип документа:
Чланак у часопису (Рецензирана верзија)
Метаподаци
Приказ свих података о документуАпстракт:
Investigations on the antitumor activity of metallacarboranes are sparse in the literature and limited to a handful of ruthena- and molybdacarboranes. In this study, the molybdacarborane fragment [3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] was combined with a vector molecule, inspired by the well-known drug tamoxifen or 4,4'-dihydroxytamoxifen (TAM-diOH). The molybdacarborane derivative [3,3-{4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine-κ2 N,N'}-3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] (10), as well as the ligand itself 4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine (6) showed cytotoxic activities in the low micromolar range against breast adenocarcinoma (MDA-MB-231, MDA-MB-361 and MCF-7), human glioblastoma (LN-229) and human glioma (U-251) cell lines. In addition, compounds 6 and 10 were found to induce senescence and cytodestructive autophagy, lower ROS/RNS levels, but only the molybdacarborane 10 induced a strong increase of nitric oxide (NO) concentration in the MCF-7 cells.
Кључне речи:
breast cancer; molybdacarborane; nanoparticles; nitric oxide (NO); tamoxifenИзвор:
ChemMedChem, 2019, 14, 24, 2075-2083Финансирање / пројекти:
- Молекуларни механизми физиолошке и фармаколошке контроле инфламације и канцера (RS-MESTD-Basic Research (BR or ON)-173013)
- Fonds der Chemischen Industrie
- School Leipzig School of Natural Sciences – Building with Molecules and Nanoobjects
DOI: 10.1002/cmdc.201900554
ISSN: 1860-7179
PubMed: 31677361
WoS: 000496886800001
Scopus: 2-s2.0-85075365747
URI
https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.201900554https://radar.ibiss.bg.ac.rs/handle/123456789/3531